Search

Your search keyword '"Pérol, M."' showing total 272 results
Start Over Author "Pérol, M." Search Limiters Full Text
272 results on '"Pérol, M."'

4. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

Author

Reck, M., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Reyes, F., Souquet, P.-J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., Paz-Ares, L., Carbone, D.P., Memaj, A., Marimuthu, S., Zhang, X., Tran, P., and John, T.

Published
2021
Full Text
View/download PDF

5. Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer

Author

Heudel, P., Chabaud, S., Perol, D., Flechon, A., Fayette, J., Combemale, P., Tredan, O., Desseigne, F., de la Fouchardiere, C., Boyle, H., Perol, M., Bachelot, T., Cassier, P., Avrillon, V., Terret, C., Michallet, A.-S., Neidhardt-Berard, E.-M., Nicolas-Virelizier, E., Dufresne, A., Belhabri, A., Brahmi, M., Lebras, L., Nicolini, F., Sarabi, M., Rey, P., Bonneville-Levard, A., Rochefort, P., Provensal, A.-M., Eberst, L., Assaad, S., Swalduz, A., Saintigny, P., Toussaint, P., Guillermin, Y., Castets, M., Coutzac, C., Meeus, P., Dupré, A., Durand, T., Crochet, H., Fervers, B., Gomez, F., Rivoire, M., Gregoire, V., Claude, L., Chassagne-Clement, C., Pilleul, F., Mognetti, T., Russias, B., Soubirou, J.-L., Lasset, C., Chvetzoff, G., Mehlen, P., Beaupère, S., Zrounba, P., Ray-Coquard, I., and Blay, J.-Y.

Published
2021
Full Text
View/download PDF

7. 76P Immune checkpoint inhibitor (ICI) retreatment patterns and outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who received second-line or later (2L+) nivolumab (nivo): A French I-O optimise analysis

Author

Justeau, G., primary, Pérol, M., additional, Valette, C. Audigier, additional, Debieuvre, D., additional, Quantin, X., additional, Lena, H., additional, Macouillard, P., additional, Bosquet, L., additional, Schoemaker, M.J., additional, Mella, M., additional, Correia, B., additional, Rault, C., additional, Daumont, M.J., additional, Penrod, J., additional, and Chouaid, C., additional

Published
2023
Full Text
View/download PDF

8. 78P Final analysis of the French real-world study EVIDENS: Effectiveness, safety & quality of life at 36 months of nivolumab in advanced non-small cell lung cancer (NSCLC)

Author

Barlesi, F., primary, Dixmier, A., additional, Debieuvre, D., additional, Raspaud, C., additional, Auliac, J.B., additional, Benoit, N., additional, Bombaron, P., additional, Moro-Sibilot, D., additional, Asselain, B., additional, Audigier-Valette, C., additional, Brellier, F., additional, Cotté, F-E., additional, and Pérol, M., additional

Published
2023
Full Text
View/download PDF

9. MA13.10 Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02

Author

Janne, P., primary, Goto, Y., additional, Kubo, T., additional, Ninomiya, K., additional, Kim, S.-W., additional, Planchard, D., additional, Ahn, M.-J., additional, Smit, E.F., additional, de Langen, A.J., additional, Pérol, M., additional, Pons-Tostivint, E., additional, Novello, S., additional, Hayashi, H., additional, Shimizu, J., additional, Kim, D.-W., additional, Pereira, K., additional, Cheng, F.-C., additional, Taguchi, A., additional, Cheng, Y., additional, and Goto, K., additional

Published
2023
Full Text
View/download PDF

12. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial

Author

Trédan, O., Wang, Q., Pissaloux, D., Cassier, P., de la Fouchardière, A., Fayette, J., Desseigne, F., Ray-Coquard, I., de la Fouchardière, C., Frappaz, D., Heudel, P.-E., Bonneville-Levard, A., Fléchon, A., Sarabi, M., Guibert, P., Bachelot, T., Pérol, M., You, B., Bonnin, N., Collard, O., Leyronnas, C., Attignon, V., Baudet, C., Sohier, E., Villemin, J.-P., Viari, A., Boyault, S., Lantuejoul, S., Paindavoine, S., Treillleux, I., Rodriguez, C., Agrapart, V., Corset, V., Garin, G., Chabaud, S., Pérol, D., and Blay, J.-Y.

Published
2019
Full Text
View/download PDF

14. A cross-sectional analysis of treatment patterns in small-cell lung cancer in five European countries

Author

Reguart, N, Pérol, M, Cortinovis, D, Puntis, S, Öhrling, K, Archangelidi, O, Louie, K, Blackhall, F, Sebastian, M, Louie, KS, Reguart, N, Pérol, M, Cortinovis, D, Puntis, S, Öhrling, K, Archangelidi, O, Louie, K, Blackhall, F, Sebastian, M, and Louie, KS

Abstract

Aim: To investigate changes in treatment patterns in extensive-stage small-cell lung cancer (ES-SCLC) in France, Germany, Italy, Spain and the UK (EU5) between 2018 and 2021. Methods: Cross-sectional data from an oncology database were analyzed retrospectively. Results: Of 5832 eligible patients, 88.4% had stage IV disease at diagnosis. Among patients receiving first-line treatment, 91.8% (1079 /1176) received the platinum-etoposide (PE) combination in 2018 which decreased to 42.3% (509/1203) by 2021. Usage of the PE-atezolizumab combination increased from 0 to 41.2% during the same timeframe. Topotecan monotherapy remained the most widely used second-line treatment regardless of patients' platinum sensitivity. Conclusion: The first-line standard of care for ES-SCLC has evolved in EU5 with the PE-atezolizumab/durvalumab combination gradually superseding PE usage.Lung cancer is the leading cause of cancer-related deaths. Small-cell lung cancer (SCLC) is fast-growing type of lung cancer. New treatments for SCLC using medicines that stimulate the immune system to kill cancer cells (called immunotherapies) have recently been approved for use in Europe. The purpose of the study was to describe the type of treatments that patients received in five European countries before and after the introduction of these new treatments to determine how quickly these new treatments were adopted in a real-world setting. This study found that most patients treated between 2018 and 2020 still received a platinum-based chemotherapy as their first anticancer therapy, but immunotherapies were used more often in later years and became the most common first treatment in 2021 for patients who had never been treated for their cancer. Topotecan, a type of chemotherapy, was the most used treatment for patients whose cancer came back after treatment. There is still a clear unmet need for new, safe and effective therapies for the treatment of patients with SCLC whose cancer comes back again after tr

Published
2023

15. 202P The therapeutic cancer vaccine PDC*lung01 induces immune responses with or without anti-PD-1 treatment in patients with non-small cell lung cancer

Author

Sibille, A., primary, Plumas, J., additional, Demedts, I., additional, Pons-Tostivint, E., additional, Van De Kerkhove, C., additional, Derijcke, S., additional, Collodoro, M., additional, Al Badawy, K., additional, Duchayne, C., additional, Debruyne, C., additional, Pérol, M., additional, Buchmeier, E.L., additional, Cuppens, K., additional, and Vansteenkiste, J.F., additional

Published
2022
Full Text
View/download PDF

16. 1176P Open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC)

Author

Vansteenkiste, J.F., primary, Demedts, I., additional, Pons-Tostivint, E., additional, Biesma, B., additional, Borm, F., additional, Colinet, B., additional, Cuppens, K., additional, Derijcke, S., additional, Greillier, L., additional, Jürgens, J., additional, Moro-Sibilot, D., additional, Pérol, M., additional, Sebastian, M., additional, Skrzypski, M., additional, Theelen, W., additional, Van De Kerkhove, C., additional, Collodoro, M., additional, Plumas, J., additional, Debruyne, C., additional, and Sibille, A., additional

Published
2022
Full Text
View/download PDF

17. 976P Phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): Registrational data from DESTINY-Lung01

Author

Li, B.T., primary, Smit, E.F., additional, Goto, Y., additional, Nakagawa, K., additional, Goto, K., additional, Mazieres, J., additional, Uprety, D., additional, Bazhenova, L., additional, Saltos, A., additional, Felip, E., additional, Pacheco, J., additional, Pérol, M., additional, Paz-Ares, L., additional, Saxena, K., additional, Shiga, R., additional, Cheng, Y., additional, Yan, Q., additional, Planchard, D., additional, and Jänne, P.A., additional

Published
2022
Full Text
View/download PDF

18. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data

Author

Pérol, M., primary, Felip, E., additional, Dafni, U., additional, Polito, L., additional, Pal, N., additional, Tsourti, Z., additional, Ton, T.G.N., additional, Merritt, D., additional, Morris, S., additional, Stahel, R., additional, and Peters, S., additional

Published
2022
Full Text
View/download PDF

19. 193P Safety and efficacy of immmunotherapy rechallenge following a previous immune-induced interstitial lung disease

Author

Joseph, C., primary, Mazieres, J., additional, Delaunay, M., additional, Lusque, A., additional, Michot, J-M., additional, Veillon, R., additional, Wislez, M., additional, Tomasini, P., additional, Giroux-Leprieur, E., additional, Duruisseaux, M., additional, Pérol, M., additional, Decroisette, C., additional, Duchemann, B., additional, Couraud, S., additional, Milia, J., additional, Collot, S., additional, Prevot, G., additional, and Le Pavec, J., additional

Published
2022
Full Text
View/download PDF

20. Efficacy of Brigatinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Who Progressed on Alectinib or Ceritinib: ALTA-2 Study

Author

Ignatius Ou SH, Nishio, M, Ahn, Mj, Mok, T, Barlesi, F, Zhou, C, Felip, E, de Marinis, F, Kim, Sw, Pérol, M, Liu, G, Migliorino, Mr, Kim, Dw, Novello, S, Bearz, A, Garrido, P, Mazieres, J, Morabito, A, Lin, Hm, Yang, H, Niu, H, Zhang, P, and Kim, Es.

Subjects
anaplastic lymphoma kinase, circulating tumor DNA, non–small cell lung cancer, tumor biomarker
Published
2022

21. Effectiveness of PD-(L)1 Inhibitors Alone or in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Non-Squamous Non-Small Cell Lung Cancer (nsq-NSCLC) With PD-L1-High Expression Using Real-World Data

Author

Pérol, M. Felip, E. Dafni, U. Polito, L. Pal, N. Tsourti, Z. Ton, T. G. N. Merritt, D. Morris, S. Stahel, R. Peters, S.

Abstract

BACKGROUND: Anti-PD-(L)1 therapy alone (cancer immunotherapy [CIT]-mono) or combined with platinum-based chemotherapy (CIT-chemo) is used as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC). Our study compared clinical outcomes with CIT-mono vs CIT-chemo in the specific clinical scenario of non-squamous (Nsq)-NSCLC with a high PD-L1 expression of ≥50\% (tumor proportion score (TPS) or tumor cells (TC)). METHODS: This was a retrospective cohort study using a real-world de-identified database. Patients with metastatic Nsq-NSCLC with high PD-L1 expression initiating first-line CIT-mono or CIT-chemo between 24 October 2016 and 28 February 2019 were followed up to 28 February 2020. We compared overall survival (OS) and real-world progression-free survival (rwPFS) using Kaplan-Meier methodology. Hazard ratios (HR) were adjusted (aHR) for differences in baseline key prognostic characteristics using inverse probability of treatment weighting methodology. RESULTS: Patients with PD-L1-high Nsq-NSCLC treated with CIT-mono (n=351), were older and less often presented with de novo stage IV disease than patients treated with CIT-chemo (n=169). With a median follow-up of 19.9 months for CIT-chemo vs 23.5 months for CIT-mono, median OS and rwPFS did not differ between the two groups (median OS: CIT-chemo, 21.0 months vs CIT-mono, 22.1 months, aHR=1.03, 95\% CI 0.77-1.39, P=0.83; median rwPFS: CIT-chemo, 10.8 months vs CIT-mono, 11.5 months, aHR=1.04, 95\% CI 0.78-1.37, P=0.81). CIT-chemo showed significant and meaningful improvement in OS and rwPFS vs CIT-mono only in the never-smoker subgroup, albeit among a small sample of patients (n=50; OS HR=0.25, 95\% CI 0.07-0.83, interaction P=0.02; rwPFS HR=0.40, 95\% CI 0.17-0.95, interaction P=0.04). CONCLUSION: Except in the subgroup of never-smoker patients, sparing the chemotherapy in first-line CIT treatment does not appear to impact survival outcomes in Nsq-NSCLC patients with high PD-L1 expression.

Published
2022

22. Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’: [ESMO Open Volume 6, Issue 5, October 2021, 100273]

Author

Reck, M., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Reyes, F., Souquet, P.-J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., Paz-Ares, L., Carbone, D.P., Memaj, A., Marimuthu, S., Zhang, X., Tran, P., and John, T.

Published
2021
Full Text
View/download PDF

23. 109P Treatment patterns in patients with advanced non-small cell lung cancer (aNSCLC) after discontinuing an immune checkpoint inhibitor (ICI) therapy in second-line or later in Germany and France

Author

Griesinger, F., primary, Pérol, M., additional, Durand-Zaleski, I., additional, Bosquet, L., additional, Zacharias, S., additional, Calleja, A., additional, Patel, S., additional, Waldenberger, D., additional, Reynaud, D., additional, Carroll, R., additional, Daumont, M.J., additional, Penrod, J.R., additional, Lacoin, L., additional, and Chouaid, C., additional

Published
2021
Full Text
View/download PDF

24. 1200P BrigALK2 study: A multicentric real-world study evaluating brigatinib in ALK positive advanced pre-treated non-small cell lung cancers: Long-term follow-up with focus on lorlatinib efficacy after brigatinib

Author

Descourt, R., primary, Pérol, M., additional, Rousseau-Bussac, G., additional, Planchard, D., additional, Mennecier, B., additional, Wislez, M., additional, Cadranel, J., additional, Cortot, A.B., additional, Guisier, F., additional, Galland, L., additional, Do, P., additional, Schott, R., additional, Dansin, E., additional, Arrondeau, J., additional, Auliac, J.B., additional, and Chouaid, C., additional

Published
2021
Full Text
View/download PDF

25. 1842P Molecular testing in older patients treated for an advanced or metastatic non-squamous non-small cell lung cancer

Author

Lamy, T., primary, Cabarrou, B., additional, Planchard, D., additional, Quantin, X., additional, Schneider, S., additional, Bringuier, M., additional, Besse, B., additional, Pérol, M., additional, Girard, N., additional, Schott, R., additional, Chouaid, C., additional, Ricordel, C., additional, Gervais, R., additional, Debieuvre, D., additional, Audigier-Valette, C., additional, Carton, M., additional, Filleron, T., additional, Simon, G., additional, Robain, M., additional, and Baldini, C., additional

Published
2021
Full Text
View/download PDF

26. 1258P MET exon14 skipping in non-small cell lung cancer: Clinicopathological characteristics, treatments, and efficacy of crizotinib according to functional analysis: AFonMET - GFPC study

Author

Babey, H., primary, Jamme, P., additional, Gervais, R., additional, Assié, J-B., additional, Veillon, R., additional, Doubre, H., additional, Pérol, M., additional, Guisier, F., additional, Huchot, E., additional, Decroisette, C., additional, Falchero, L., additional, Chiappa, A-M., additional, André, M., additional, Cortot, A.B., additional, Chouaid, C., additional, Le Gac, G., additional, and Descourt, R., additional

Published
2021
Full Text
View/download PDF

27. LBA45 Primary data from DESTINY-Lung01: A phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC)

Author

Li, B.T., primary, Smit, E.F.F., additional, Goto, Y., additional, Nakagawa, K., additional, Udagawa, H., additional, Mazieres, J., additional, Nagasaka, M., additional, Bazhenova, L., additional, Saltos, A.N., additional, Felip, E., additional, Pacheco, J.M., additional, Pérol, M., additional, Paz-Ares, L., additional, Saxena, K., additional, Shiga, R., additional, Cheng, Y., additional, Acharyya, S., additional, Shahidi, J., additional, Planchard, D., additional, and Jänne, P.A., additional

Published
2021
Full Text
View/download PDF

28. 1348P Long-term survival and health-related quality of life with nivolumab for previously-treated advanced non-small cell lung cancer (NSCLC): A wide prospective French real-world study (EVIDENS)

Author

Barlesi, F., primary, Dixmier, A., additional, Debieuvre, D., additional, Raspaud, C., additional, Auliac, J.B., additional, Nicolas, B., additional, Bombaron, P., additional, Moro-Sibilot, D., additional, Audigier-Valette, C., additional, Asselain, B., additional, Dumanoir, J., additional, Cotté, F-E., additional, Allan, V., additional, Calvet, C., additional, Reynaud, D., additional, and Pérol, M., additional

Published
2021
Full Text
View/download PDF

29. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.

Author

Reck, M, Ciuleanu, T-E, Cobo, M, Schenker, M, Zurawski, B, Menezes, J, Richardet, E, Bennouna, J, Felip, E, Juan-Vidal, O, Alexandru, A, Sakai, H, Lingua, A, Reyes, F, Souquet, P-J, De Marchi, P, Martin, C, Pérol, M, Scherpereel, A, Lu, S, Paz-Ares, L, Carbone, DP, Memaj, A, Marimuthu, S, Zhang, X, Tran, P, John, T, Reck, M, Ciuleanu, T-E, Cobo, M, Schenker, M, Zurawski, B, Menezes, J, Richardet, E, Bennouna, J, Felip, E, Juan-Vidal, O, Alexandru, A, Sakai, H, Lingua, A, Reyes, F, Souquet, P-J, De Marchi, P, Martin, C, Pérol, M, Scherpereel, A, Lu, S, Paz-Ares, L, Carbone, DP, Memaj, A, Marimuthu, S, Zhang, X, Tran, P, and John, T

Abstract

BACKGROUND: To further characterize survival benefit with first-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone, we report updated data from the phase III CheckMate 9LA trial with a 2-year minimum follow-up. PATIENTS AND METHODS: Adult patients were treatment naïve, with stage IV/recurrent non-small-cell lung cancer, no known sensitizing EGFR/ALK alterations, and an Eastern Cooperative Oncology Group performance status ≤1. Patients were randomized 1 : 1 to nivolumab 360 mg every 3 weeks plus ipilimumab 1 mg/kg every 6 weeks with two cycles of chemotherapy, or four cycles of chemotherapy. Updated efficacy and safety outcomes are reported, along with progression-free survival (PFS) after next line of treatment (PFS2), treatment-related adverse events (TRAEs) by treatment cycle, and efficacy outcomes in patients who discontinued all treatment components in the experimental arm due to TRAEs. RESULTS: With a median follow-up of 30.7 months, nivolumab plus ipilimumab with chemotherapy continued to prolong overall survival (OS) versus chemotherapy. Median OS was 15.8 versus 11.0 months [hazard ratio 0.72 (95% confidence interval 0.61-0.86)]; 2-year OS rate was 38% versus 26%. Two-year PFS rate was 20% versus 8%. ORR was 38% versus 25%, respectively; 34% versus 12% of all responses were ongoing at 2 years. Median PFS2 was 13.9 versus 8.7 months. Improved efficacy outcomes in the experimental versus control arm were observed across most subgroups, including by programmed death-ligand 1 and histology. No new safety signals were observed; onset of grade 3/4 TRAEs was mostly observed during the first two treatment cycles in the experimental arm. In patients who discontinued all components of nivolumab plus ipilimumab with chemotherapy treatment due to TRAEs (n = 61) median OS was 27.5 months; 56% of responders had an ongoing response ≥1 year after discontinuation. CONCLUSIONS: With a 2-year minimum follow-up, nivolumab plus ipilimumab wi

Published
2021

30. LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01

Author

Ahn, M-J., Lisberg, A., Paz-Ares, L., Cornelissen, R., Girard, N., Pons-Tostivint, E., Vicente Baz, D., Sugawara, S., Cobo Dols, M., Pérol, M., Mascaux, C., Poddubskaya, E., Kitazono, S., Hayashi, H., Sands, J., Hall, R., Zhang, Y., Zebger-Gong, H., Uema, D., and Okamoto, I.

Published
2023
Full Text
View/download PDF

32. 147P Non-small cell lung cancer: Artificial intelligence enables the identification of survival signatures complementary to an Immunologically active gene expression signature involving previous therapies

Author

Saintigny, P., Iriso, P., Afshar, M., Attignon, V.K., Auclair, J., Boulahfa, J., Boussageon, M., Fayette, J., Foy, J-P., Karabajakian, A., Kindermans, M., Lamkhioued, M., Lantuejoul, S., Michon, L., Ortiz-Cuaran, S., Parmentier, F., Pérol, M., Swalduz, A., and Turcat, T.

Published
2023
Full Text
View/download PDF

40. 1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A

Author

Gadgeel, S.M., Mok, T.S.K., Peters, S., Nadal, E., Han, J-Y., Alatorre Alexander, J.A., Leighl, N., Sriuranpong, V., Pérol, M., Castro, G.D., de Marinis, F., Tan, D.S.W., Paul, S., Assaf, Z.J., MacLennan, M., Lohmann, T.O., Slade, M., Mathisen, M.S., Bhagawati-Prasad, V., and Dziadziuszko, R.

Published
2023
Full Text
View/download PDF

41. 1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02

Author

Li, B.T., Planchard, D., Goto, K., Smit, E.F., De Langen, J., Goto, Y., Ninomiya, K., Kubo, T., Pérol, M., Felip, E., Hayashi, H., Nakagawa, K., Shimizu, J., Nagasaka, M., Pereira, K.M.C., Taguchi, A., Ali, A., Karnoub, M., Yonemochi, R., and Jänne, P.A.

Published
2023
Full Text
View/download PDF

44. 110P Real-world evaluation of pembrolizumab monotherapy for previously treated PD-L1 positive (TPS>1%) advanced NSCLC in France

Author

Pérol, M., primary, Quantin, X., additional, Lena, H., additional, Filleron, T., additional, Chouaid, C., additional, Valette, C. Audigier, additional, Kaderbhai, C., additional, Chenuc, G., additional, Santorelli, M., additional, Bensimon, L., additional, Burke, T., additional, Simon, G., additional, Martin, A-L., additional, Debieuvre, D., additional, Gervais, R., additional, Schott, R., additional, Carton, M., additional, Courtinard, C., additional, and Girard, N., additional

Published
2021
Full Text
View/download PDF

45. 109P Real-world evaluation of pembrolizumab monotherapy for PD-L1 positive (TPS>50%) metastatic NSCLC in France

Author

Pérol, M., primary, Filleron, T., additional, Quantin, X., additional, Chouaid, C., additional, Valette, C. Audigier, additional, Lena, H., additional, Kaderbhai, C., additional, Fabre, C., additional, Santorelli, M., additional, Bensimon, L., additional, Burke, T., additional, Couch, D., additional, Nguyen, E., additional, and Courtinard, C., additional

Published
2021
Full Text
View/download PDF

48. 1325P Long-term survival and health-related quality of life in patients treated with nivolumab for advanced non-small cell lung cancer: A wide prospective French real-world study (EVIDENS)

Author

Barlesi, F., primary, Dixmier, A., additional, Debieuvre, D., additional, Raspaud, C., additional, Auliac, J.B., additional, Benoit, N., additional, Bombaron, P., additional, Moro-Sibilot, D., additional, Audigier-Valette, C., additional, Asselain, B., additional, Dumanoir, J., additional, Cotte, F-E., additional, Allan, V., additional, Ozan, N., additional, Calvet, C.Y., additional, Reynaud, D., additional, and Pérol, M., additional

Published
2020
Full Text
View/download PDF

49. 1242P Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

Author

Girard, N., primary, Fietkau, R., additional, Garassino, M., additional, Garrido, P., additional, Field, J.K., additional, Peters, S., additional, Smit, H.J.M., additional, Pérol, M., additional, Merle, P., additional, Sibille, A., additional, Markman, B., additional, Bouchaab, H., additional, Moskovitz, M., additional, Schumann, C., additional, Gregorc, V., additional, Klein, A.B., additional, Diaz Perez, I., additional, Sawyer, W., additional, Licour, M., additional, and Christoph, D., additional

Published
2020
Full Text
View/download PDF

50. 1392P Brigatinib in patients with ALK-positive advanced non-small cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)

Author

Descourt, R., primary, Pérol, M., additional, Planchard, D., additional, Rousseau-Bussac, G., additional, Mennecier, B., additional, Wislez, M., additional, Cadranel, J., additional, Cortot, A.B., additional, Guisier, F., additional, Do, P., additional, Schott, R., additional, Dansin, E., additional, Arrondeau, J., additional, Auliac, J.B., additional, Chouaid, C., additional, and Galland, L., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results